CKM Syndrome Explained for UK Adults 2026: The 5 Stages of Cardiovascular-Kidney-Metabolic Health

A UK GP-clinic explainer of CKM (cardiovascular-kidney-metabolic) syndrome in 2026. AHA 2023 framework, 5 stages from 0 healthy to 4 clinical CVD, NHS Health Check and QRISK3 as the screening backbone, and modern treatments like SGLT2 inhibitors, GLP-1 agonists and finerenone that work across multiple CKM organs at once. Around 90 percent of UK adults are at Stage 1 or higher.

If your GP has recently started talking about your heart and kidneys in the same breath, you are not imagining a shift in approach. Across the UK, general practice is moving towards a more connected view of health, for conditions like high blood pressure, type 2 diabetes and raised cholesterol.

This change has been formalised by the 2023 American Heart Association Presidential Advisory on cardiovascular-kidney-metabolic (CKM) syndrome. This framework recognises that heart disease, kidney disease, diabetes, obesity and fatty liver are not separate problems but interconnected parts of the same biological system. A major UK Biobank study of over 400,000 people has since confirmed that these CKM stages strongly predict the risk of death in the UK population. This article explains what CKM syndrome means for you, the five stages from healthy to clinical disease, how the NHS is applying this thinking and the practical steps you can take at your next GP appointment.

What CKM syndrome actually is and why the AHA introduced it in 2023

CKM stands for Cardiovascular-Kidney-Metabolic syndrome. It is not a new disease, but a new framework for understanding a group of existing, closely linked conditions. The underlying biology is shared: chronic inflammation, oxidative stress, insulin resistance, overactivation of the renin-angiotensin-aldosterone system (RAAS) and neurohormonal dysfunction create a state where damage in one organ system accelerates damage in the others.

For example, insulin resistance in type 2 diabetes promotes fatty liver disease and damages blood vessels, while high blood pressure strains both the heart and the kidneys. The American Heart Association’s October 2023 Presidential Advisory formally grouped these conditions to encourage a unified treatment approach, moving away from fragmented care where a patient might see a cardiologist, a nephrologist and an endocrinologist separately without coordinated plans.

In the UK, this concept is already being operationalised through the NHS England Cardiovascular, Renal, Metabolic (CVRM) programme, which aims to integrate pathways across primary and secondary care to manage these interconnected risks more effectively.

The 5 stages of CKM (with the UK numbers that matter)

The AHA framework defines five stages of CKM syndrome, providing a roadmap from health to established disease.

How the UK NHS actually uses this in 2026 (QRISK3, NHS Health Check, CVRM)

While the CKM framework is influential, UK NHS practice in 2026 remains anchored to its own established tools. The primary cardiovascular risk assessment tool used in general practice is QRISK3, not the American PREVENT calculator. The NICE guideline NG238 on cardiovascular risk assessment, updated in 2023, confirms QRISK3 as the standard for primary prevention in England and Wales.

QRISK3 is relevant because it already incorporates many CKM elements: age, sex, ethnicity, BMI, smoking status, diabetes, blood pressure, cholesterol ratio, kidney disease (stages 3-5), atrial fibrillation and rheumatoid arthritis.

The backbone of population screening is the NHS Health Check, offered free every five years to adults aged 40 to 74. This check assesses BMI, blood pressure, cholesterol and blood glucose or HbA1c and often includes kidney function (eGFR), effectively capturing CKM Stages 0 to 2 for millions.

The NHS England CVRM programme is actively working to break down traditional siloes between cardiovascular, renal and metabolic care pathways, ensuring that the connected nature of these conditions is reflected in how services are delivered.

Modern treatments that work across the whole CKM web

The most significant therapeutic advance aligned with CKM thinking is the development of drug classes that benefit multiple organ systems simultaneously.

SGLT2 inhibitors (such as dapagliflozin, empagliflozin and canagliflozin) were developed for type 2 diabetes but are now first-line for heart failure (regardless of ejection fraction), chronic kidney disease with proteinuria and diabetes with high cardiovascular risk. One medication, three organ benefits.

GLP-1 receptor agonists (like semaglutide, tirzepatide and liraglutide) also offer a triple benefit: improving blood sugar control, promoting significant weight loss and reducing cardiovascular events. The SELECT trial, for instance, showed semaglutide reduced major heart attacks and strokes in overweight individuals without diabetes but with prior cardiovascular disease.

Finerenone (Kerendia) is a newer non-steroidal mineralocorticoid receptor antagonist approved by NICE for treating CKD in people with type 2 diabetes. These are complemented by foundational medications like statins for LDL cholesterol and ACE inhibitors/ARBs for blood pressure and kidney protection.

The key point is that these are not separate drugs for separate diseases, they are treatments for the interconnected CKM web.

Lifestyle foundation that applies at every CKM stage

Regardless of your CKM stage or what medications you take, lifestyle change is the non-negotiable foundation for management.

The evidence consistently supports a Mediterranean-style or DASH diet pattern: rich in vegetables, fruit, whole grains, oily fish, olive oil, nuts and legumes, with limited red and processed meat.

Physical activity guidance recommends at least 150 minutes of moderate-intensity exercise per week, plus resistance or strength training on two days.

Weight management is critical, even a 5-10% reduction in body weight can measurably improve blood pressure, blood sugar, cholesterol and liver fat.

Stopping smoking remains the single most effective action to reduce cardiovascular risk.

Alcohol intake should be within the UK guideline of 14 units per week, spread over several days.

Prioritising 7-9 hours of sleep per night and addressing stress and mental health are also recognised components of holistic CKM management.

In short, lifestyle is not an optional extra-it is what makes medical treatments work effectively.

What to ask for at your next NHS GP review (the practical checklist)

Being proactive at your GP appointment can ensure a full CKM assessment.

When CKM symptoms become urgent and what to do

While CKM management is often about long-term risk reduction, certain symptoms require urgent action.

Call 999 or go directly to A&E for: chest pain with sweating, breathlessness or pain radiating to the jaw or arm (possible heart attack), sudden one-sided weakness, slurred speech, facial droop or loss of vision (use the FAST test for possible stroke), severe, sudden breathlessness or coughing up blood.

Call NHS 111 or request an urgent same-day GP appointment for: gradually worsening breathlessness over days, significant new swelling of your legs or ankles, rapid weight gain of more than 2kg in a few days (suggesting fluid retention), new, persistent heart palpitations or passing little urine.

Book a routine GP appointment for: a gradual decline in fitness, new and persistent fatigue, leg pain on walking that eases with rest (claudication) or a trend of declining kidney function on your blood test results.

Frequently Asked Questions

Is CKM syndrome a new disease or just rebranding?

It is not a new disease but a new framework for organising care. The AHA 2023 advisory grouped heart, kidney, metabolic and liver diseases under one heading because they share biology and progress together. The benefit is unified care, reducing the risk of fragmented treatment across separate clinics. Critics argue it merely names what good GPs already do, but proponents say a unified shorthand helps prevent important connections being missed.

What stage of CKM am I?

The precise answer requires your specific numbers. Roughly: no risk factors is Stage 0, being overweight is Stage 1, having diabetes, high blood pressure, high cholesterol or kidney disease is Stage 2, a high QRISK3 score or silent artery disease is Stage 3 and an actual heart attack, stroke or heart failure is Stage 4. Ask your GP to share your QRISK3 score and recent blood results to understand your position.

Does the NHS use the AHA PREVENT calculator or QRISK3?

The UK NHS uses QRISK3, not the AHA PREVENT score. The NICE NG238 guideline (2023) confirms QRISK3 as the standard primary prevention tool in the UK. It was developed for the UK population and is integrated into GP computer systems. It already incorporates key CKM factors like kidney disease, diabetes and BMI, making it a practical fit for this integrated approach.

Why does my GP want a urine sample if my bloods are fine?

A urine albumin to creatinine ratio (ACR) test detects tiny amounts of albumin leaking into the urine, which is one of the earliest signs of kidney and cardiovascular damage. This can be abnormal years before your eGFR (from a blood test) starts to drop. NICE recommends annual urine ACR for everyone with diabetes and for those with high blood pressure or other CKM risk factors. It is a important early-warning signal in the CKM picture.

Should I be on an SGLT2 inhibitor for my CKM risk?

It is a possibility worth discussing. NICE recommends SGLT2 inhibitors for heart failure (any type), chronic kidney disease with proteinuria and type 2 diabetes with high cardiovascular risk. These drugs benefit the heart, kidneys and metabolic system together. Ask your GP if you meet any of these criteria. Common side effects include genital thrush and increased urination, but for the right patient, they are a transformative treatment class.

Can I reverse my CKM stage?

Earlier stages are often reversible with sustained effort. Moving from Stage 1 (excess weight) back to Stage 0 is possible with 5-10% weight loss, improved diet and regular movement. Stage 2 metabolic risks like high blood pressure or prediabetes can also be reversed with lifestyle changes. Stage 2 CKD and Stages 3-4 are usually not reversible, but their progression can be slowed with modern medication and lifestyle management, making early action critically important.

I am perimenopausal and have raised blood pressure and cholesterol. Am I CKM Stage 2?

Based on those findings, you would likely be classified at CKM Stage 2. This stage includes high blood pressure (≥140/90 mmHg) and raised cholesterol. The perimenopause increases cardiovascular risk as ooestrogen, which has a protective effect, declines. Ask your GP for a full CKM workup, including your QRISK3 score and have a discussion about managing your blood pressure and lipids, which may include considering HRT where appropriate, alongside foundational lifestyle measures.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.